Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Fc gamma receptor IIb (FCGR2B)
- Target
- FCGR2B
- Molecular classification
- Receptor, Type I Fc gamma receptor, Cell surface protein
01
Overview
Fc gamma receptor IIb (FCGR2B) is a low affinity inhibitory receptor for the Fc region of immunoglobulin gamma (IgG), uniquely distinguished by the presence of an immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic region. It is primarily expressed on B cells, monocytes, basophils, and dendritic cells, where it regulates immune responses by inhibiting cellular activation, promoting phagocytosis of immune complexes, and down-regulating antibody production. There are distinct isoforms generated through alternative splicing which differ in their cellular localization and regulatory functions. Genetic polymorphisms or reduced function of FcγRIIb are linked to susceptibility to various autoimmune diseases. This receptor is being investigated as a therapeutic target in autoimmunity and oncology, both to suppress harmful immune activation and as part of engineered antibody therapies.
- Other names
- Low affinity immunoglobulin gamma Fc region receptor IIbFc gamma receptor IIBFcγRIIbFc-gamma-RIIBCD32BIgG Fc receptor II betaLymphocyte antigen 17Ly-17
02
Mechanism of action
Antibody-dependent cellular phagocytosis (ADCP) Down-regulation of B-cell, T-cell, and mast cell activation via immunoreceptor tyrosine-based inhibitory motif (ITIM) signaling Negative feedback for antibody production
03
Biological functions
Immune responseNegative regulation of B cell activationPhagocytosis of immune complexesRegulation of antibody productionModulation of cellular activation
04
Disease associations
Autoimmune disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, Goodpasture's syndrome, multiple sclerosis)InflammationCancer (as a potential immunotherapy target)Infection (role in antibody-mediated immunity)
05
Safety considerations
Risk of excessive immunosuppression if overactivatedPotential exacerbation of infection or interference with protective antibody responsesPolymorphisms associated with increased autoimmunity risk
06
Interacting drugs
Monoclonal antibodies (e.g., anti-FcγRIIb antibodies for autoimmune diseases; experimental, various preclinical/clinical candidates)
2 more in the full profile.
07
Biomarkers
FCGR2B polymorphisms (disease susceptibility/biomarker for autoimmune risk)Expression levels on B cells (biomarker in certain lymphoproliferative/autoimmune diseases)
Beyond the preview
Go deeper on Fc gamma receptor IIb (FCGR2B).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fc gamma receptor IIb (FCGR2B).